Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer

Annals of Surgical Oncology

Volumn 13, Issue 6, 2006, Pages 783-787

  Escobar, Pedro F ^a   Patrick, Rebecca J ^a   Rybicki, Lisa A ^a   Hicks, David ^a   Weng, David E ^a   Crowe, Joseph P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Advanced breast cancer; Axillary lymph nodes; Clinical outcome; Metastatic breast cancer; Primary induction chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PREOPERATIVE CARE; PRIMARY INDUCTION CHEMOTHERAPY; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33646550565     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.07.024     Document Type: Article

References (28)

1. Adair F, Berg J, Joubert L, Robbins GF. Long term follow-up of breast cancer patients: the 30-year report. Cancer 1996; 33:1145-50.
2. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990; 66:1387-91.
3. Bear HD. Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 1998; 25:3-12.
4. Schwartz GF, Birchansky CA. Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73:362-9.
5. Jakesz R. The ABCSG: comparison of pre- vs. postoperative chemotherapy in breast cancer patients-four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) trial 7 (abstract). Proc Am Soc Clin Oncol 2001; 20:125.
6. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-93.
7. Scholl SM, Fouquet A, Asselain B, et al. Primary versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial. Eur J Cancer 1994; 30A:645-52.
8. van der Hage JA, van de Velde CJH, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224-37.
9. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-85.
10. Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000; 83:1480-7.
11. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer. Significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456-66.
12. Rajan R, Esteva FJ, Symmans WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response. Clin Breast Cancer 2004; 5:235-8.
13. Colleoni M, Zahrieh D, Gelber RD, et al. Preoperative systemic treatment: prediction of responsiveness. Breast 2003; 12:538-42.
14. Penault-Llorca F, Bouchet MF, Amat S, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 2003; 22:1319-25.
15. Newman LA, Pernick NL, Adsay V, et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 2003; 10:713-5.
16. Arimappamagan A, Kadambari D, Srinivasan K, et al. Complete axillary conversion after neoadjuvant chemotherapy in locally advanced breast cancer: a step towards conserving axilla?. Indian J Cancer 2004; 41:13-7.
17. Kling KM, Ostrzega N, Schmit P. Breast conservation after induction chemotherapy for locally advanced breast cancer. Am Surg 1997; 6:861-4.
18. Valagussa P. Prognostic factors in locally advanced noninflammatory breast cancer: long-term results following primary chemotherapy. Breast Cancer Res Treat 1990; 15:137-47.
19. Hortobagyi GN. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62:2507-16.
20. Zanbetti M. Combined sequential approach in locally advanced breast cancer. Ann Oncol 1999; 10:305-10.
21. Danforth DN, Zujewski J, O'Shaughnessy J, et al. Selection of local therapy after neoadjuvant chemotherapy in patients with stage III A, B breast cancer. Ann Surg Oncol 1998; 5:150-8.
22. Schwartz GF, Cantor RI, Biermann WA. Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast. Arch Surg 1987; 122:1430-4.
23. Kuer HM, Newman LA, Fornage BD, et al. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol 1998; 5:673-80.
24. Gajdos C, Tartter P, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ. Relationship of clinical and pathological response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002; 80:4-11.
25. Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol 2003; 10:1152-9.
26. Lenert JT, Vlastos G, Mirza NQ, et al. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 1999; 6:762-7.
27. Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004; 22:4067-77.
28. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21:2600-8.